Illudent Therapeutics
- Biotech or pharma, therapeutic R&D
Advancing ITX-121, a small molecule that potently and selectively kills cancer cells that are deficient in the NER (nucleotide-excision repair) pathway. We are advancing it as a precision medicine (patients will be selected by biomarkers) to treat multiple types of solid tumors. Potential first-in-class for this compound class and first-in-class for this patient population.
We are raising $4m to complete IND-enabling studies and to broaden our data package in advance of Series A to fund clinical trials.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}